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Abstract
Introduction: Henoch-Schönlein purpura is a small vessel vasculitis that affects mainly the skin,
joints, gastrointestinal tract and kidneys. The central nervous system is also occasionally affected,
although the majority of patients experience only mild symptoms such as headaches and
behavioural changes. Intracerebral haemorrhage is a rare complication of Henoch-Schönlein
purpura that so far has mainly been described in children and young adolescence.
Case presentation: We describe a 42-year-old man with Henoch-Schönlein purpura who
developed an acute intracerebral haemorrhage that coincided with a reactivation of his vasculitis
and the development of renal failure following discontinuation of steroids. In this patient, both the
Henoch-Schönlein purpura and his neurological symptoms were successfully treated with
intravenous cyclophosphamide and methylprednisolone, followed by a short course of oral
cyclophosphamide and long-term oral prednisolone. His renal function also recovered sufficiently
not to require renal replacement therapy.
Conclusion: The management of Henoch-Schönlein nephritis remains unclear, especially in the
presence of severe complications such as intracerebral haemorrhage. We describe a successful
outcome in such a patient.
Introduction
Henoch-Schönlein purpura (HSP) is a small vessel vascu-
litis characterized by IgA1 deposition in the renal mesan-
gium and in the blood vessels. It is seen most frequently
in early childhood, although it can occur at any age [1,2].
It is usually preceded by upper respiratory tract infections,
having a peak incidence in the autumn and winter [1,2].
In most cases it is a self-limiting disorder and tends to
resolve within 1 month of presentation, although it can
re-occur in a third of cases [1,2].
HSP affects mainly the skin, joints, gastrointestinal tract
and kidneys [1-3]. The severity of symptoms is usually
worse in older patients, who tend to have more frequent
skin, joint and renal involvement [2]. The central nervous
system is also occasionally affected, although the majority
of patients experience only mild symptoms such as head-
aches and behavioural changes [3]. More serious neuro-
logical complications are rare and include seizures, cranial
or peripheral neuropathies, intracerebral haemorrhage
and encephalopathy [1,3]. We describe a man with HSP
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coincided with a reactivation of his vasculitis.
Case presentation
A 42-year-old man presented with acute onset of a vascu-
litic rash on his buttocks and feet, abdominal pain and
arthralgia. This had been preceded by an episode of sore
throat 10 days previously. He was found to be hyperten-
sive with a blood pressure (BP) of 158/104 mmHg and he
had marked peripheral oedema. He was not known to be
hypertensive and he had no other past medical history.
Urine dipstick was positive for 3+ of blood and 4+ of pro-
tein. His urinary protein to creatinine ratio (PCR) was ele-
vated at 283. There was a significant increase of his serum
creatinine from 108 to 152 μmol/l. He received three
doses of intravenous methylprednisolone 500 mg, fol-
lowed by oral cyclophosphamide 100 mg once daily and
prednisolone 60 mg once daily. Antineutrophil cytoplas-
mic antibodies and antinuclear antibodies were negative.
A renal biopsy was performed which showed diffuse pro-
liferative glomerulonephritis with marked IgA staining
compatible with Henoch-Schönlein nephritis (Figures 1
and 2). Over the following few days his serum creatinine
increased to 300 μmol/l, but subsequently returned to
151 μmol/l. His rash and the other systemic features also
resolved. In the absence of any crescents in the renal
biopsy, the cyclophosphamide was discontinued and he
was discharged home on oral prednisolone 50 mg daily.
However, because of severe indigestion despite taking
omeprazole 20 mg once daily, the prednisolone was
reduced to 30 mg once daily soon after.
Upon review 2 weeks later the patient's rash had returned
and he remained hypertensive with a BP of 145/95
mmHg. He was therefore prescribed azathioprine 100 mg
and ramipril 1.25 mg daily and the prednisolone was
increased again to 40 mg once daily. Unfortunately he was
again unable to tolerate the increased dose of steroids due
to gastrointestinal side effects and the prednisolone was
therefore discontinued.
One week later he presented to the accident and emer-
gency department with sudden onset of a severe head-
ache, right-sided weakness and expressive dysphasia,
followed by a generalized seizure. He was hypertensive
with a BP of 194/115 but with no papilloedema. Initial
investigations showed a serum creatinine concentration
of 438 μmol/l, haemoglobin of 11.2 g/dl, a white cell
count of 10.9 × 109/litre, a platelet count of 2269 × 109/
litre, prothrombin time of 14 seconds and activated par-
tial thromboplastin time of 28 seconds. He was trans-
ferred to the intensive therapy unit where he was
intubated and ventilated for 24 hours. A computed tom-
ography scan of his head confirmed a large left internal
capsule haemorrhage, but showed no mass effect (Figure
3). He was treated with four doses of intravenous methyl-
prednisolone 500 mg and one dose of intravenous cyclo-
phosphamide 750 mg, which was followed by oral
prednisolone 40 mg once daily and cyclophosphamide
100 mg once daily. Although his dysphasia and weakness
were improving, his renal function declined rapidly and
he required haemodialysis.
The cyclophosphamide was discontinued 2 weeks later
and the patient was discharged home on oral pred-
nisolone 25 mg once daily. Four weeks after the acute
admission he had made an almost complete recovery
from the intracerebral haemorrhage apart from some mild
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need renal replacement therapy. One year later he remains
well and dialysis-independent with a serum creatinine of
295 μmol/l, but has continued taking oral prednisolone
10 mg once daily, a dose which is gradually being
reduced. His PCR has improved to 87 and urine dipstick
has remained positive for blood 1+ and protein 1+.
Discussion
Intracerebral haemorrhage is a rare complication of HSP
that so far has mainly been described in children and
young adolescents [3-9]. Apart from this case, there is only
one other published report in an older patient, to the best
of our knowledge [10]. Such patients may develop acute
elevations in BP, and this is considered to be the primary
mechanism of intracerebral haemorrhage [11]. However,
other possible causes include the presence of cerebral vas-
culitis and the increased risk of haemorrhagic complica-
tions seen in patients with HSP. The increased risk of
bleeding in HSP has been attributed to reduced levels of
factor XIII [4] and prothrombin [5]. Other reported sites
of bleeding in patients with HSP include the gastrointesti-
nal tract, lungs, testicles and bladder [6]. Intracerebral
haemorrhage in patients with HSP has been successfully
treated in the past with surgical evacuation of the hae-
matoma [7], steroids [8] or plasmapheresis if cerebral vas-
culitis is confirmed by magnetic resonance imaging [9].
The underlying coagulopathy should also be corrected
[4,5].
HSP nephritis may affect as many as 80% of adult patients
with HSP and approximately 30% of them will develop
chronic kidney disease [2]. Adverse prognostic indicators
for progression of HSP nephritis are the presence of cres-
cents on biopsy, more than 1 g of proteinuria per 24 hours
and renal impairment on presentation [2]. The optimal
treatment of HSP nephritis remains unclear, because of
the lack of prospective randomized trials. Intravenous
pulse methylprednisolone followed by oral steroids has
been shown to be effective in the management of severe
HSP nephritis [12]. Other possible treatment regimens for
severe HSP nephritis include a combination of corticoster-
oids with cyclophosphamide, azathioprine or cyclosporin
[1,2].
Conclusion
Intracerebral haemorrhage is a rare complication of HSP
that may be caused by acute hypertension, cerebral vascu-
litis, and the increased risk of bleeding observed in this
disorder. Although our patient was severely hypertensive
at the time of presentation, both the HSP nephritis and his
neurological symptoms were successfully treated with
intravenous cyclophosphamide and methylprednisolone,
followed by a short course of oral cyclophosphamide and
long-term oral prednisolone. His renal function recovered
enough not to require renal replacement therapy.
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